Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13:00 | Enzymatica AB: Enzymatica to Support Swedish Biathlon Federation as Official Supplier | 17 | GlobeNewswire (Europe) | Enzymatica is proud to announce a partnership with the Swedish Biathlon Federation, under which Enzymatica becomes an Official Supplier to the national federation.
The collaboration focuses on initiatives... ► Artikel lesen | |
22.08. | Enzymatica AB: Bulletin from the Extraordinary General Meeting of Enzymatica AB (publ) on 22 August 2025 | 107 | GlobeNewswire (Europe) | On 22 August 2025, the shareholders of Enzymatica AB (publ) (the "Company") held an Extraordinary General Meeting. The following principal resolutions were adopted at the Meeting.
Election of Board... ► Artikel lesen | |
12.08. | Enzymatica AB: Sana Alajmovic appointed new CEO of Enzymatica AB | 145 | GlobeNewswire (Europe) | The Board of Directors of Enzymatica AB (publ) has appointed Sana Alajmovic as the new Chief Executive Officer. She succeeds Claus Egstrand, who has announced that he is stepping down from his operational... ► Artikel lesen | |
ENZYMATICA Aktie jetzt für 0€ handeln | |||||
06.08. | Notice of Extraordinary General Meeting in Enzymatica AB (publ) | 1 | Cision News | ||
17.07. | Quarterly report Q2/2025: Strong development in Sweden and increased international activity: Enzymatica AB | 283 | PR Newswire | LUND, Sweden, July 17, 2025
/PRNewswire/ --
Second quarter
Net sales reached SEK 8.3 (6.4) million.The operating result totaled SEK -14.9 (-13.5) million.Earnings per... ► Artikel lesen | |
17.07. | ENZYMATICA AB: Quarterly report Q2/2025: Strong development in Sweden and increased international activity | 3 | Cision News | ||
30.06. | Enzymatica AB: Enzymatica's CFO Therese Filmersson to leave her position | 124 | GlobeNewswire (Europe) | Enzymatica AB (publ) announces today that the company's Chief Financial Officer (CFO), Therese Filmersson, has decided to leave her position. The decision has been made in mutual agreement between Therese... ► Artikel lesen | |
26.06. | Enzymatica AB: Claus Egstrand steps down as CEO of Enzymatica | 289 | GlobeNewswire (Europe) | The CEO of Enzymatica AB, Claus Egstrand, is stepping down from his role and will join the company's Board of Directors. Recruitment of a new CEO has begun. The change will ensure long-term stability... ► Artikel lesen | |
07.05. | Bulletin from the annual general meeting of Enzymatica AB (publ) on May 7, 2025 | 1 | Cision News | ||
05.05. | ENZYMATICA AB: Enzymatica gears up for global expansion after a strong first quarter | 3 | Cision News | ||
29.04. | Enzymatica AB: Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion | 258 | PR Newswire | LUND, Sweden, April 29, 2025 /PRNewswire/ --
First quarter
Net sales amounted to SEK 12.3 million (9.4).Operating result amounted to SEK -18.0 million (-18.4).Earnings per share... ► Artikel lesen | |
28.02. | Enzymatica AB: Invitation to Press Briefing - 5 March 2025 | 347 | PR Newswire | STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB invites to a digital press briefing... ► Artikel lesen | |
28.02. | Enzymatica AB: New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms | 408 | PR Newswire | STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- Today, results from two independent studies on the medical device ColdZyme were published in the peer-reviewed scientific journal The Journal of Physiology.... ► Artikel lesen | |
18.02. | Enzymatica AB: Year-end report 2024: Strong performance in core markets - preparing for international growth | 258 | PR Newswire | LUND, Sweden, Feb. 18, 2025 /PRNewswire/ --
Fourth quarter
January-December
• Net sales reached SEK 17.2 million (15.8).
• The operating result totaled SEK -13.7... ► Artikel lesen | |
07.11.24 | Enzymatica AB's Interim report Q3/2024: Focus on developing existing and new markets | 453 | PR Newswire | LUND, Sweden, Nov. 7, 2024 /PRNewswire/ --
Third quarter
January-September
Net sales reached SEK 12.6 (13.3) million. The operating result totaled... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 29,640 | +6,95 % | BAYER erreicht Meilenstein bei Parkinson-Medikament | Im Januar hatte BAYER von der US-Arzneimittelbehörde FDA die Erlaubnis erhalten, das Parkinson-Medikament Bemdaneprocel nach dem positiven Abschluss der Phase I direkt in die zulassungsrelevante Phase... ► Artikel lesen | |
NOVO NORDISK | 50,16 | +6,46 % | Novo Nordisk: Großer Wurf? - DEAG, Knaus Tabbert, PNE, Renk und TUI im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
PFIZER | 23,115 | +6,52 % | Buy or Goodbye?: Apple, BMW, Wacker Chemie, Henkel und Pfizer - Die Analystenstimmen des Tages | © Foto: Andrej Sokolow/dpaApple, BMW, Wacker Chemie, Henkel und Pfizer: Die wichtigsten Analysten-Updates im Überblick.UBS stuft Apple auf "Neutral" Die Schweizer Großbank UBS hat die Einstufung für... ► Artikel lesen | |
GILEAD SCIENCES | 95,38 | +0,88 % | Gilead Sciences: Wann bricht sie aus? | Der Pharmariese Gilead Sciences verzeichnet wichtige Entwicklungen im Portfolio und neue regulatorische Entscheidungen. Die jüngsten Ereignisse eröffnen frische Chancen, die den Konzern auf einen nachhaltigen... ► Artikel lesen | |
SANOFI | 84,66 | +5,65 % | Kurs der Sanofi SA-Aktie verharrt auf Vortags-Niveau (79,71 €) | An der Börse ist das Wertpapier von Sanofi SA gegenwärtig unauffällig. Das Papier notiert derzeit bei 79,71 Euro. Einen minimalen Wertverlust von 0,19 Prozent zeigt die Kurstafel für die Aktie von Sanofi... ► Artikel lesen | |
GSK | 19,335 | +6,59 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK anlässlich des angekündigten Wechsels an der Führungsspitze mit einem Kursziel von 1486 Pence auf "Underweight" belassen.... ► Artikel lesen | |
ABBVIE | 205,00 | +3,96 % | AbbVie strebt Markteinführung von ELAHERE in Großbritannien an | Der US-Pharmakonzern AbbVie will sein Krebsmedikament ELAHERE auch in Großbritannien einführen - und zwar zu einem Listenpreis, der dem US-Niveau entspricht. Voraussetzung für den Start ist allerdings... ► Artikel lesen | |
CANOPY GROWTH | 1,190 | -4,03 % | As Trump Promotes CBD, Should You Buy, Sell, or Hold Canopy Growth Stock? | ||
STADA ARZNEIMITTEL | - | - | Italy's private equity weekly roundup. News from Named Group, White Bridge Investments, Stada Arzneimittel, TA Associates, Cinven, Carlyle, Charterhouse, Advent, Raiway, EI Towers, F2i, and more | ||
ASTRAZENECA | 143,15 | +11,57 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca auf "Overweight" mit einem Kursziel von 14000 Pence belassen. Richard Vosser rechnet laut seinem am Montag vorliegenden... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
INNOCAN PHARMA | 10,960 | +11,27 % | InnoCan Pharma: Mit Nasdaq-IPO-Kapital auf FDA-Kurs?! | ||
TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | CSE Bulletin: Suspensions - Blender Bites Limited, TAAT Global Alternatives Inc. | Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2025) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as... ► Artikel lesen | |
CRONOS GROUP | 2,280 | -3,96 % | CRONOS - Cannabis-Aktie explodiert ans Rallyziel! | ||
VIATRIS | 8,660 | +2,63 % | Viatris: The Importance of a Global, Resilient Supply Chain to Access | NORTHAMPTON, MA / ACCESS Newswire / September 30, 2025 / People everywhere need access to the right treatment at the right time. However, far too many people face barriers getting the care they need.... ► Artikel lesen |